NxStage Medical Inc. (NASDAQ:NXTM) CEO Jeffrey H. Burbank sold 7,500 shares of the business’s stock in a transaction dated Wednesday, November 23rd. The shares were sold at an average price of $24.01, for a total transaction of $180,075.00. Following the completion of the transaction, the chief executive officer now owns 897,616 shares in the company, valued at $21,551,760.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of NxStage Medical Inc. (NASDAQ:NXTM) opened at 25.24 on Friday. The company’s 50-day moving average is $24.31 and its 200-day moving average is $22.52. NxStage Medical Inc. has a 12-month low of $13.49 and a 12-month high of $26.83. The company’s market cap is $1.63 billion.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Hedge funds have recently made changes to their positions in the company. Acrospire Investment Management LLC raised its stake in shares of NxStage Medical by 1,459.3% in the second quarter. Acrospire Investment Management LLC now owns 4,678 shares of the medical device company’s stock worth $101,000 after buying an additional 4,378 shares in the last quarter. Pacad Investment Ltd. bought a new stake in shares of NxStage Medical during the second quarter worth approximately $111,000. BNP Paribas Arbitrage SA raised its stake in shares of NxStage Medical by 57.5% in the second quarter. BNP Paribas Arbitrage SA now owns 5,548 shares of the medical device company’s stock worth $120,000 after buying an additional 2,026 shares in the last quarter. BlackRock Inc. raised its stake in shares of NxStage Medical by 50.6% in the second quarter. BlackRock Inc. now owns 6,299 shares of the medical device company’s stock worth $136,000 after buying an additional 2,116 shares in the last quarter. Finally, Cutler Group LP raised its stake in shares of NxStage Medical by 28.3% in the second quarter. Cutler Group LP now owns 7,168 shares of the medical device company’s stock worth $155,000 after buying an additional 1,583 shares in the last quarter. Hedge funds and other institutional investors own 98.86% of the company’s stock.

A number of analysts recently commented on the stock. BTIG Research restated a “buy” rating and set a $29.00 price target on shares of NxStage Medical in a research note on Sunday, August 7th. Canaccord Genuity restated a “buy” rating and set a $28.00 price target on shares of NxStage Medical in a research note on Thursday, November 3rd. Zacks Investment Research upgraded shares of NxStage Medical from a “hold” rating to a “strong-buy” rating and set a $24.00 price target on the stock in a research note on Thursday, November 3rd. Northland Securities set a $25.00 price target on shares of NxStage Medical and gave the company a “buy” rating in a research note on Thursday, September 15th. Finally, Jefferies Group upped their price target on shares of NxStage Medical from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $25.67.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2016/11/25/jeffrey-h-burbank-sells-7500-shares-of-nxstage-medical-inc-nxtm-stock-2.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

5 Day Chart for NASDAQ:NXTM

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.